News about Global Pharma

Jubilant HollisterStier Expands Spokane Facility with USD 132 Million Sterile Fill & Finish Line Launch

Jubilant HollisterStier LLC (JHS) — a wholly owned subsidiary of Jubilant Pharmova and a leading North American contract manufacturer specialising in sterile injectables — has launched a new Sterile Fill & Finish line, its third at the Spokane manufacturing facility in Washington, USA.

Global Pharma | 10/10/2025 | By Dineshwori |  254

Thermo Fisher Launches Molecular Microscope to Assess Lung Transplant Rejection

Thermo Fisher’s new Molecular Microscope Diagnostic System for Lung (MMDx Lung) leverages the power of Machine Learning (ML) to profile gene expression data from lung biopsies, comparing each new sample to a reference set of over 896 lung biopsies.

Global Pharma | 10/10/2025 | By Dineshwori |  136

Boehringer Ingelheim's Jascayd Receives US FDA Approval for Oral Treatment Option for Adults with IPF

Jascayd is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of action that exerts both antifibrotic and immunomodulatory effects, thereby slowing the decline in lung function in IPF patients.

Global Pharma | 10/10/2025 | By Dineshwori |  448

XenoTherapeutics Completes Takeover of Canada's ESSA Pharma

Canada-based ESSA Pharma has announced the completion of its acquisition by XenoTherapeutics, a US-based research foundation focused on advancing xenotransplantation therapies.

Global Pharma | 10/10/2025 | By Dineshwori |  363

Samsung Biologics Launches ExellenS Framework to Standardize and Accelerate Biomanufacturing Operations

By deploying the ExellenS framework across its manufacturing network—with standardised designs, unified processes, and advanced digital integration—Samsung Biologics ensures plant equivalency, operational speed, and seamless manufacturing continuity.

Global Pharma | 10/10/2025 | By Dineshwori |  254

Complement Therapeutics Receives US FDA Clearance to Begin Opti-GAIN Phase-I/II Trial of CTx001 in Patients with GA Secondary to AMD

CTx001, an AAV-based gene therapy, delivers a mini-CR1 protein to modulate complement pathways and address Geographic Atrophy (GA), an advanced dry AMD causing irreversible vision loss.

Global Pharma | 09/10/2025 | By Dineshwori |  159

Turbine Partners with AstraZeneca to Accelerate Antibody-Drug Conjugate Discovery

Turbine, a leading company specialising in virtualising biological experiments through artificial intelligence (AI), has announced a new collaboration with AstraZeneca to enhance the discovery of antibody-drug conjugates (ADCs).

Global Pharma | 09/10/2025 | By Dineshwori |  269

CND Life Sciences Receives US FDA Breakthrough Device Designation for its Skin Biopsy-based Syn-One Test

CND Life Sciences has received FDA Breakthrough Device Designation for its Syn-One Test, designed to aid in diagnosing synucleinopathies in patients aged 40 years and above with neurological symptoms.

Global Pharma | 09/10/2025 | By Dineshwori |  250

Lupin Launches Strategic Partnership Programme to Expand Reach of PrecisionSphere

Global pharma major Lupin has launched a strategic partnership programme aimed at expanding the reach of PrecisionSphere – the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi.

Global Pharma | 09/10/2025 | By Dineshwori |  187

Edan Instruments Expands US Footprint with New Manufacturing Hub in San Diego

Chinese medical device manufacturer EDAN Instruments has strengthened its presence in the United States with the opening of a new manufacturing hub in San Diego, California.

Global Pharma | 09/10/2025 | By Dineshwori |  235